January 5, 2001
NEAL S. PENNEYS, M.D. JOINS AMERIPATH
Riviera Beach, FL, January 5, 2001 - AmeriPath Inc,
(NASDAQ: PATH), the nation's largest company focused
on providing anatomic pathology, cancer diagnostic and
related healthcare information services, proudly announced
today that Neal S. Penneys, M.D. plans to join the south
Florida staff of dermatopathologists as of February 1,
2001.
For almost 30 years, Dr. Penneys has worked closely
with physicians and students around the world. Most
recently, Dr. Penneys has served as the Associate Dean
and Chief Operating Officer of the University Medical
Group at Saint Louis Health Sciences Center as well as
Professor of Dermatology, Medicine, Pathology and Pediatrics. Prior
to joining the Saint Louis University School of Medicine,
Dr. Penneys was the Professor of Dermatology at the University
of Miami. Dr. Penneys is the Immediate Past President
of the American Society of Dermatopathology. In addition
to receiving numerous honors and awards for his work,
he has lectured extensively in the United States and
abroad. He has authored over 300 articles, and has contributed
to numerous books and book chapters.
AmeriPath's Chairman and Chief Executive Officer, James
C. New, commented, "We are pleased and honored that Dr.
Penneys has joined our team of dermatopathologists. His
experience and reputation as a leader in dermatopathology
reinforces the strength of our medical staff, and confirms
AmeriPath's commitment to providing quality pathology
services to our referring physicians and the medical
community. Dr. Penneys will also develop a new education
initiative in Florida which will include basic dermatopathology
training seminars for dermatologists and more advanced
instruction for dermatopathologists."
AmeriPath, Inc. is the nation's largest company focused
on providing anatomic pathology, cancer diagnostic and
related healthcare information services to physicians,
hospitals, national clinical laboratories and managed
care organizations. The Company's 425 physicians provide
medical services through 42 outpatient pathology laboratories,
224 hospital inpatient laboratories, and 64 outpatient
surgery centers in 21 states.
..............................................................................................
The statements of James C. New and
other statements contained in this press release
are "forward-looking
statements" which are based on current beliefs and expectations.
Past performance is not necessarily indicative of future
results. In addition, forward-looking statements - which
are identified by words such as "may", "should", "believe," "expect," "anticipate" and
similar expressions -- are subject to a number of risks
and uncertainties which could cause actual results to
differ materially from historical results or those expected
or anticipated. These include risks and uncertainties
relating to satisfaction of closing conditions, demand
for pathology services, pricing, federal and state regulation
(and compliance), reimbursement rates, government and
third party payments, the ability to attract, motivate,
and retain pathologists, dependence upon pathologists
and contracts, the development and expansion of managed
care and national clinical lab contracts, completion
and integration of acquisitions and affiliations (and
achievement of planned or expected synergies), competitive
factors and technology. Further information regarding
risks, uncertainties and other factors that could affect
the Company's financial results, or could cause actual
results to differ materially from those expected or anticipated,
are included in the Company's Form 10-K for the year
ended December 31, 1999 and subsequent filings with the
SEC.
